Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: J Addict Med. 2020 Jul-Aug;14(4):282–286. doi: 10.1097/ADM.0000000000000572

Table 1:

Summary of demographic and clinical variables, mortality, and repeat episode of endocarditis among those who received buprenorphine, received methadone, or declined MOUD during the index admission

Total (n=26) Received buprenorphine (n=8) Received methadone (n=8) Declined MOUD (n=10) p
Age, M (SD)  33.8 (SD 12.0) 31.1 (SD 10.6) 38.9 (SD 14.4) 31.9 (SD 11.3) NS

Gender
 Female 13 (50%) 5 (62.5%) 5 (62.5%) 3 (30%) NS
 Male 13 (50%) 3 (37.5%) 3 (37.5%) 7 (70%)

Race
 White 22 (84.6%) 7 (87.5%) 7 (87.5%) 8 (80.0%) NS
 Black 1 (3.8%) 0 1 (12.5%) 0
 Asian 1 (3.8%) 1 (12.5%) 0 0
 Unknown 2 (7.7%) 0 0 2 (20.0%)

Ethnicity
 Not Hispanic or Latino 24 (92.3%) 8 (100%) 8 (100.0%) 8 (80.0%) NS
 Hispanic or Latino 0 0 0 0
 Unknown 2 (7.7%) 0 0 2 (20.0%)

Psychiatric history
 History of psychiatric admission 8 (30.8%) 3 (37.5%) 3 (37.5%) 2 (20.0%) NS
 On psychiatric medications 11 (42.3%) 2 (25.0%) 4 (50.0%) 5 (50.0%) NS
 Any psychiatric disorder 15 (57.7%) 4 (50.0%) 5 (62.5%) 6 (60.0%) NS
  Mood disorder 11 (42.3%) 4 (50.0%) 3 (37.5%) 4 (40.0%) NS
  Anxiety disorder 11 (42.3%) 4 (50.0%) 3 (37.5%) 4 (40.0%) NS
  PTSD 4 (15.4%) 1 (12.5%) 2 (25.0%) 1 (12.5%) NS

SUD history
 Opioid use disorder 26 (100.0%) 8 (100.0%) 8 (100.0%) 10 (100.0%) NS
  IV heroin 24 (92.3%) 8 (100.0%) 7 (87.5%) 9 (90.0%) NS
  IV prescription opioid 4 (15.4%) 0 2 (25.0%) 2 (20.0%) NS
  IV buprenorphine 4 (15.4%) 1 (12.5%) 2 (25.0%) 1 (10.0%) NS
 Cocaine/stimulant use disorder 13 (50.0%) 4 (50.0%) 3 (37.5%) 6 (60.0%) NS
 Cannabis use disorder 8 (30.8%) 3 (37.5%) 2 (25.0%) 3 (30.0%) NS
 Alcohol use disorder 8 (30.8%) 5 (62.5%) 1 (12.5%) 2 (20.0%) NS
 Prior overdose 3 (11.5%) 0 2 (25.0%) 1 (10.0%) NS
 Prior MOUD 14 (53.9%) 5 (62.5%) 5 (62.5%) 4 (40.0%) NS

Medical history
 Chronic pain 7 (26.9%) 1 (12.5%) 4 (50.0%) 2 (20.0%) NS
 Hepatitis C 15 (57.7%) 6 (75.0%) 4 (50.0%) 5 (50.0%) NS
 HIV 0 0 0 0 NS
 Previous endocarditis 8 (30.8%) 3 (37.5%) 3 (37.5%) 2 (20.0%) NS
 Prosthetic valve 6 (23.1%) 3 (37.5%) 2 (25.0%) 1 (10.0%) NS

Transferred from another hospital at index admission 15 (57.7%) 5 (62.5%) 5 (62.5%) 5 (50.0%) NS

Site of infection
 Tricuspid 12 (48.0%) 5 (62.5%) 4 (57.1%) 3 (30.0%) NS
 Pulmonary 1 (4.0%) 1 (12.5%) 0 0
 Mitral 5 (20.0%) 1 (12.5%) 3 (42.9%) 1 (10.0%)
 Aortic 6 (24.0%) 1 (12.5%) 0 5 (50.0%)
 No vegetations 1 (4.0%) 0 0 1 (10.0%)
 Prosthetic valve infection 6 (23.1%) 3 (37.5%) 2 (25.0%) 1 (10.0%) NS

Bacteria
 MRSA 5 (19.2%) 2 (25.0%) 1 (12.5%) 2 (20.0%) NS
 MSSA 13 (50.0%) 4 (50.0%) 6 (75.0%) 3 (30.0%)
 Streptococcus 4 (15.4%) 1 (12.5%) 0 3 (30.0%)
 Enterococcus 3 (11.5%) 0 1 (12.5%) 2 (20.0%)
 Unknown 1 (3.9%) 1 (12.5%) 0 0

Hospital length of stay, Mean days (SD) 17.8 (SD 13.9) 16.6 (SD 11.7) 15.0 (SD 7.7) 21,0 (19.1) NS

Surgical treatment at index admission 8 (30.8%) 3 (37.5%) 1 (25.0%) 3 (30.0%) NS

Antibiotic treatment
 Completion of antibiotic course 24 (92.3%) 8 (100.0%) 6 (75.0%) 10 (100.0%) NS
 Transferred to nursing facility 23 (88.5%) 7 (87.5%) 7 (87.5%) 9 (90.0%) NS

Duration of follow-up, Mean months, (SD, range) 45.0 (SD 7.2, range 34–56) 45.8 (SD 7.0, 35–54) 43.8 (SD 8.7, 34–54) 45.3 (SD 6.7, 35–56) NS

Mortality (% deceased) 15.4% 0 3 (37.5%) 1 (10%) NS

Repeat episode of endocarditis 10 (38.5%) 4 (50.0%) 2 (25%) 4 (40%) NS

Evidence of MOUD after index admission during follow-up 16 (61.5%) 7 (87.5%) 4 (50%) 5 (50%) NS

MOUD = Medications for opioid use disorder

PTSD = Post-traumatic stress disorder

MRSA = Methicillin-Resistant Staphylococcus Aureus

MSSA = Methicillin-Susceptible Staphylococcus Aureus